MX2018004127A - Anticuerpos que neutralizan potencialmente el virus de hepatitis b y usos de los mismos. - Google Patents

Anticuerpos que neutralizan potencialmente el virus de hepatitis b y usos de los mismos.

Info

Publication number
MX2018004127A
MX2018004127A MX2018004127A MX2018004127A MX2018004127A MX 2018004127 A MX2018004127 A MX 2018004127A MX 2018004127 A MX2018004127 A MX 2018004127A MX 2018004127 A MX2018004127 A MX 2018004127A MX 2018004127 A MX2018004127 A MX 2018004127A
Authority
MX
Mexico
Prior art keywords
antibodies
hepatitis
virus
relates
potently neutralize
Prior art date
Application number
MX2018004127A
Other languages
English (en)
Inventor
Corti Davide
Original Assignee
Humabs Biomed Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humabs Biomed Sa filed Critical Humabs Biomed Sa
Publication of MX2018004127A publication Critical patent/MX2018004127A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082Hepadnaviridae, e.g. hepatitis B virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse transcribing DNA viruses
    • C12N2730/00011Details
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere e anticuerpos, y fragmentos de enlace a antígeno de los mismos, que se enlazan a la región de bucle antigénico del antígeno superficial de hepatitis B (HBsAg) y neutralizan potencialmente la infección tanto del virus de hepatitis B (HBV) como el virus de hepatitis delta (HDV). La invención también se refiere a epítopos a los cuales los anticuerpos y fragmentos de enlace a antígenos de los mismos, así como ácidos nucleicos que codifican y las células que producen estos anticuerpos y fragmentos de anticuerpos. Además, la invención se refiere al uso de los anticuerpos y fragmentos de anticuerpo de la invención en la diagnosis, profilaxis y el tratamiento de hepatitis B y hepatitis D.
MX2018004127A 2015-10-07 2016-10-07 Anticuerpos que neutralizan potencialmente el virus de hepatitis b y usos de los mismos. MX2018004127A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2015/001970 WO2017059878A1 (en) 2015-10-07 2015-10-07 Antibodies that potently neutralize hepatitis b virus and uses thereof
PCT/EP2016/074114 WO2017060504A1 (en) 2015-10-07 2016-10-07 Antibodies that potently neutralize hepatitis b virus and uses thereof

Publications (1)

Publication Number Publication Date
MX2018004127A true MX2018004127A (es) 2018-06-13

Family

ID=54330711

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018004127A MX2018004127A (es) 2015-10-07 2016-10-07 Anticuerpos que neutralizan potencialmente el virus de hepatitis b y usos de los mismos.

Country Status (25)

Country Link
US (3) US10683344B2 (es)
EP (2) EP3753949A1 (es)
JP (3) JP6869968B2 (es)
KR (1) KR20180056777A (es)
CN (3) CN114539392B (es)
AU (1) AU2016334735B2 (es)
BR (1) BR112018002406A2 (es)
CA (1) CA2993745A1 (es)
CY (1) CY1123462T1 (es)
DK (1) DK3359564T3 (es)
EA (1) EA038301B1 (es)
ES (1) ES2813927T3 (es)
HK (1) HK1256869A1 (es)
HR (1) HRP20201345T1 (es)
HU (1) HUE050231T2 (es)
IL (1) IL258326B (es)
LT (1) LT3359564T (es)
MX (1) MX2018004127A (es)
MY (1) MY187161A (es)
PH (1) PH12018500199A1 (es)
PL (1) PL3359564T3 (es)
PT (1) PT3359564T (es)
SI (1) SI3359564T1 (es)
WO (2) WO2017059878A1 (es)
ZA (1) ZA201800710B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017059878A1 (en) * 2015-10-07 2017-04-13 Humabs Biomed Sa Antibodies that potently neutralize hepatitis b virus and uses thereof
JP2021522864A (ja) * 2018-05-10 2021-09-02 クリアビー セラピューティクス リミテッド B型肝炎感染症を処置するための方法および組成物
EP3793603A4 (en) * 2018-05-16 2022-01-26 Chang Gung Memorial Hospital, Linkou NEW LRRN1 (LEUCINE-RICH REPEAT NEURONAL PROTEIN 1) ANTIBODIES AND THEIR USES
US11932681B2 (en) 2018-05-31 2024-03-19 Novartis Ag Hepatitis B antibodies
CN118108836A (zh) * 2018-12-19 2024-05-31 胡默波斯生物医学公司 中和乙型肝炎病毒的抗体和其用途
EA202191736A1 (ru) * 2018-12-20 2021-10-01 Вир Байотекнолоджи, Инк. Комбинированная терапия hbv
KR102084912B1 (ko) * 2019-01-17 2020-03-05 주식회사 녹십자 B형 간염 바이러스 표면 항원의 입체 에피토프 및 이에 특이적으로 결합하는 항체
JP2022542035A (ja) * 2019-07-20 2022-09-29 フアフイ ヘルス リミテッド 抗pre-s1 hbv抗体を用いるhbv感染症の治療方法
EP4021578A1 (en) 2019-08-29 2022-07-06 VIR Biotechnology, Inc. Antibody compositions and methods for treating hepatitis b virus infection
CN113717283B (zh) * 2020-05-25 2023-05-26 厦门万泰凯瑞生物技术有限公司 一种抗乙型肝炎病毒e抗原的单克隆抗体及其应用
AU2021296848A1 (en) 2020-06-24 2023-02-09 Humabs Biomed Sa Engineered hepatitis B virus neutralizing antibodies and uses thereof
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
TW202245838A (zh) 2021-01-26 2022-12-01 美商維爾生物科技股份有限公司 用於治療b型肝炎病毒感染的組成物及方法
CN113234144B (zh) * 2021-05-26 2022-02-25 武汉工程大学 一种人源性抗乙肝表面抗原的单链抗体、制剂、编码基因、载体质粒及宿主细胞
WO2023287352A2 (en) * 2021-07-15 2023-01-19 National University Of Singapore Anti-hbv antibodies and uses thereof
CN113777312B (zh) * 2021-09-03 2024-02-02 普十生物科技(北京)有限公司 乙肝抗体片段的制备方法、乙肝抗体片段、试剂盒及应用
WO2023039243A2 (en) * 2021-09-13 2023-03-16 Achelois Biopharma, Inc. Hepatitis b virus antivirus (hbv-antivirus) compositions and methods of use
WO2023122555A2 (en) * 2021-12-21 2023-06-29 Hbvtech, Llc. Methods for eliminating hepatitis b virus cccdna and rcdna and the hepatitis b drugs used in the methods thereof
WO2023230439A1 (en) 2022-05-23 2023-11-30 Vir Biotechnology, Inc. Fc-engineered hepatitis b virus neutralizing antibodies and uses thereof
CN116162153A (zh) * 2022-09-01 2023-05-26 复旦大学附属中山医院 一种乙肝病毒表面抗原的单克隆抗体及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
EP0098110B1 (en) 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
CA2251904A1 (en) 1996-04-18 1997-10-23 Abbott Laboratories An antigenic epitope of the a determinant of hepatitis b surface antigen and uses thereof
GB9608626D0 (en) * 1996-04-25 1996-07-03 Univ College Of London Hepatitis b monoclonal antibodies
WO1998029442A1 (en) * 1996-12-30 1998-07-09 Innogenetics N.V. ANNEXIN V-BINDING POLYPEPTIDES DERIVED FROM HBsAg AND THEIR USES
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
EP1597280B2 (en) 2003-02-26 2016-08-24 Institute for Research in Biomedicine Monoclonal antibody production by ebv transformation of b cells
WO2005000898A2 (en) 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
CA2594922A1 (en) * 2005-01-14 2006-07-20 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Monoclonal antibodies that bind or neutralize hepatitis b virus
CN101802197A (zh) 2007-05-14 2010-08-11 比奥根艾迪克Ma公司 单链FC(ScFc)区、包含其的结合多肽及与其相关的方法
KR20090056537A (ko) * 2007-11-30 2009-06-03 주식회사 녹십자 B형 간염 바이러스 중화능을 갖는 항체를 유효성분으로포함하는 b형 간염 바이러스 감염의 예방 또는 치료용조성물
ES2525346T3 (es) 2008-10-22 2014-12-22 Institute For Research In Biomedicine Métodos para producir anticuerpos a partir de células plasmáticas
MX361522B (es) * 2012-08-30 2018-12-10 Replicor Inc Uso de agentes farmacéuticos para la preparacion de un medicamento para el tratamiento de hepatitis b y hepatitis d.
CN104955837A (zh) * 2012-11-12 2015-09-30 海德堡吕布莱希特-卡尔斯大学 Hbv和/或hdv易感细胞、细胞系和非人动物的开发
SG11201605691VA (en) * 2014-01-16 2016-08-30 Mario Umberto Francesco Mondelli Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen
WO2017059878A1 (en) * 2015-10-07 2017-04-13 Humabs Biomed Sa Antibodies that potently neutralize hepatitis b virus and uses thereof

Also Published As

Publication number Publication date
HRP20201345T1 (hr) 2020-11-27
EA038301B1 (ru) 2021-08-06
ZA201800710B (en) 2019-05-29
CN108137675A (zh) 2018-06-08
IL258326B (en) 2021-10-31
EP3359564A1 (en) 2018-08-15
KR20180056777A (ko) 2018-05-29
CN114539392A (zh) 2022-05-27
US20230303663A1 (en) 2023-09-28
BR112018002406A2 (pt) 2018-09-18
EP3753949A1 (en) 2020-12-23
US20190016785A1 (en) 2019-01-17
PL3359564T3 (pl) 2020-11-30
IL258326A (en) 2018-05-31
US10683344B2 (en) 2020-06-16
HK1256869A1 (zh) 2019-10-04
CN114539392B (zh) 2024-01-26
US11390664B2 (en) 2022-07-19
HUE050231T2 (hu) 2020-11-30
CN108137675B (zh) 2022-03-22
AU2016334735B2 (en) 2022-10-27
WO2017060504A1 (en) 2017-04-13
SI3359564T1 (sl) 2020-10-30
LT3359564T (lt) 2020-10-26
JP2018535650A (ja) 2018-12-06
AU2016334735A1 (en) 2018-02-15
CA2993745A1 (en) 2017-04-13
EA201890874A1 (ru) 2018-11-30
CY1123462T1 (el) 2022-03-24
US20210040183A1 (en) 2021-02-11
PT3359564T (pt) 2020-09-04
JP2021121188A (ja) 2021-08-26
ES2813927T3 (es) 2021-03-25
PH12018500199A1 (en) 2018-08-13
JP2023011809A (ja) 2023-01-24
DK3359564T3 (da) 2020-08-17
MY187161A (en) 2021-09-06
CN114539391A (zh) 2022-05-27
JP6869968B2 (ja) 2021-05-12
JP7171809B2 (ja) 2022-11-15
EP3359564B1 (en) 2020-06-03
WO2017059878A1 (en) 2017-04-13

Similar Documents

Publication Publication Date Title
PH12018500199A1 (en) Antibodies that potently neutralize hepatitis b virus and uses thereof
PH12018502348A1 (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
ZA202104213B (en) Antibodies that neutralize hepatitis b virus and uses thereof
PH12020550025A1 (en) Multispecific antibodies specifically binding to zika virus epitopes and uses thereof
PH12017500727A1 (en) Modified virus-like particles of cmv
EA201391170A1 (ru) Терапевтическое средство на основе дрожжей для лечения хронического гепатита b
PH12021550521A1 (en) Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof
EA201691611A1 (ru) Конструкции белка uspa2 и их применения
MX2015008847A (es) Composiciones inmunogenicas de virus de influenza y usos de las mismas.
EA202091513A1 (ru) Вакцины против вируса гепатита b (hbv) и их применение
SG10201806025TA (en) Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen
EA201692279A1 (ru) Способ уменьшения иммуногенности белка и пептида
WO2016061504A3 (en) Recombinant antibodies that recongnize the c-terminal domains of ebola virus nucleoprotein
WO2014150822A3 (en) Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use
MY163742A (en) Epitope and its use of hepatitis b virus surface antigen
WO2016075546A3 (en) Antibodies that neutralize ebola virus and uses thereof
WO2018066999A3 (en) Chimeric enterovirus virus-like particles
WO2019075300A3 (en) Mayaro virus consensus antigens, dna antibody constructs for use against mayaro virus, and combinations thereof
EA202191706A1 (ru) Антитела, нейтрализирующие вирус гепатита в, и их применение
EA202191994A1 (ru) Конформационный эпитоп поверхностного антигена гепатита в и антитело, специфично связывающееся с ним
EA201891048A1 (ru) Антитело, нейтрализующее респираторно-синцитиальный вирус человека
MX358496B (es) Terapeuticos a base de levadura para infeccion de la hepatitis b cronica.